The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape
Abstract
It has become clear that cancer is not merely a growth of autonomously proliferating cells, but that other non‐malignant cell types are a functional part of the disease. Immune cells, fibroblasts, specialized mesenchymal cells and microvasculature together make up the tumour microenvironment and have functional interactions with tumour cells. Classical Hodgkin's lymphoma (cHL) is characterized by only a few malignant cells and an abundance of inflammatory cells. Hodgkin and Reed–Sternberg (HRS) cells are surrounded by T and B cells admixed with plasma cells, macrophages, eosinophils and mast cells. A constitutive activity of NF‐κB and an altered JAK–STAT signalling pathway are part of the biological background associated with the increased expression of cytokines and cytokine receptors seen in HRS cells. Over‐expression of the members of the TNF receptor family, especially CD30 and CD40, is a hallmark of HRS cells. cHL is a tumour where aberrant cytokine production contributes not only to the proliferation of HRS cells but also to the maintenance of an appropriate environment for the tumour cells. In addition, several chemokines contribute to the composition of the inflammatory background in cHL. This review summarizes updated information on the complex interactions between the HRS cells and their tissue microenvironment and highlights the development of newer therapeutic strategies aimed at targeting the non‐malignant inflammatory/immune cellular components of HL that are involved in cancer cell growth and/or immune escape. Copyright © 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO classification of haematolymphoid tumours
Gaillard, F., Weerakkody, Y., & Sharma, R. (2010) · Radiopaedia.org · doi:10.53347/rid-9250 · Cited by 3,776
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity
Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., Rietz, C., Flies, D. B., Lau, J. S., Zhu, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.1089.65.3 · Cited by 1,018
Raab, M. S., Podar, K., Breitkreutz, I., Richardson, P. G., & Anderson, K. C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60221-x · Cited by 697
The biology of Hodgkin's lymphoma
Küppers, R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2542 · Cited by 688
Blank, C., Gajewski, T. F., & Mackensen, A. (2005) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-004-0593-x · Cited by 637
The microenvironment in mature B-cell malignancies: a target for new treatment strategies
Burger, J. A., Ghia, P., Rosenwald, A., & Caligaris-Cappio, F. (2009) · Blood · doi:10.1182/blood-2009-06-225326 · Cited by 577
Frequent inactivation of A20 in B-cell lymphomas
Kato, M., Sanada, M., Kato, I., Sato, Y., Takita, J., Takeuchi, K., Niwa, A., Chen, Y., Nakazaki, K., Nomoto, J., et al. (2009) · Nature · doi:10.1038/nature07969 · Cited by 555
Di Stasi, A., De Angelis, B., Rooney, C. M., Zhang, L., Mahendravada, A., Foster, A. E., Heslop, H. E., Brenner, M. K., Dotti, G., & Savoldo, B. (2009) · Blood · doi:10.1182/blood-2009-03-209650 · Cited by 533
Iwai, Y. (2004) · International Immunology · doi:10.1093/intimm/dxh194 · Cited by 527
Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma
Marshall, N. A., Christie, L. E., Munro, L. R., Culligan, D. J., Johnston, P. W., Barker, R. N., & Vickers, M. A. (2004) · Blood · doi:10.1182/blood-2003-07-2594 · Cited by 509
The role of cytokines in classical Hodgkin lymphoma
Skinnider, B. F., & Mak, T. W. (2002) · Blood · doi:10.1182/blood-2002-01-0099 · Cited by 505
The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology
Vereecke, L., Beyaert, R., & van Loo, G. (2009) · Trends in Immunology · doi:10.1016/j.it.2009.05.007 · Cited by 482
TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma
Schmitz, R., Hansmann, M.-L., Bohle, V., Martin-Subero, J. I., Hartmann, S., Mechtersheimer, G., Klapper, W., Vater, I., Giefing, M., Gesk, S., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090528 · Cited by 481
Falini, B., Fizzotti, M., Pucciarini, A., Bigerna, B., Marafioti, T., Gambacorta, M., Pacini, R., Alunni, C., Natali–Tanci, L., Ugolini, B., et al. (2000) · Blood · doi:10.1182/blood.v95.6.2084 · Cited by 475
PD-1–PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma
Yamamoto, R., Nishikori, M., Kitawaki, T., Sakai, T., Hishizawa, M., Tashima, M., Kondo, T., Ohmori, K., Kurata, M., Hayashi, T., et al. (2008) · Blood · doi:10.1182/blood-2007-05-085159 · Cited by 401
High Expression of the CC Chemokine TARC in Reed-Sternberg Cells
van den Berg, A., Visser, L., & Poppema, S. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65424-7 · Cited by 367
Dorfman, D. M., Brown, J. A., Shahsafaei, A., & Freeman, G. J. (2006) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000209855.28282.ce · Cited by 358
Juszczynski, P., Ouyang, J., Monti, S., Rodig, S. J., Takeyama, K., Abramson, J., Chen, W., Kutok, J. L., Rabinovich, G. A., & Shipp, M. A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706017104 · Cited by 327
The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation
Riley, J. L., & June, C. H. (2005) · Blood · doi:10.1182/blood-2004-04-1596 · Cited by 315
Ishida, T., Ishii, T., Inagaki, A., Yano, H., Komatsu, H., Iida, S., Inagaki, H., & Ueda, R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0261 · Cited by 291
Chetaille, B., Bertucci, F., Finetti, P., Esterni, B., Stamatoullas, A., Picquenot, J. M., Copin, M. C., Morschhauser, F., Casasnovas, O., Petrella, T., et al. (2008) · Blood · doi:10.1182/blood-2008-07-168096 · Cited by 257
Terasawa, T., Lau, J., Bardet, S., Couturier, O., Hotta, T., Hutchings, M., Nihashi, T., & Nagai, H. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0861 · Cited by 254
Expression of CCL5 (RANTES) and CCR5 in prostate cancer
Vaday, G. G., Peehl, D. M., Kadam, P. A., & Lawrence, D. M. (2006) · The Prostate · doi:10.1002/pros.20306 · Cited by 230
Chiu, A., Xu, W., He, B., Dillon, S. R., Gross, J. A., Sievers, E., Qiao, X., Santini, P., Hyjek, E., Lee, J.-W., et al. (2007) · Blood · doi:10.1182/blood-2006-04-015958 · Cited by 228
Zheng, B., Fiumara, P. F., Li, Y. V., Georgakis, G. V., Snell, V., Younes, M., Vauthey, J., Carbone, A., & Younes, A. (2003) · Blood · doi:10.1182/blood-2002-11-3507 · Cited by 213
Self-citationRescue of “crippled” germinal center B cells from apoptosis by Epstein-Barr virus
Mancao, C., Altmann, M., Jungnickel, B., & Hammerschmidt, W. (2005) · Blood · doi:10.1182/blood-2005-06-2341 · Cited by 203
Baumforth, K. R. N., Birgersdotter, A., Reynolds, G. M., Wei, W., Kapatai, G., Flavell, J. R., Kalk, E., Piper, K., Lee, S., Machado, L., et al. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.070845 · Cited by 200
Prognostic impact of tumour‐infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma
Schreck, S., Friebel, D., Buettner, M., Distel, L., Grabenbauer, G., Young, L. S., & Niedobitek, G. (2009) · Hematological Oncology · doi:10.1002/hon.878 · Cited by 188
Lenalidomide for the Treatment of B-Cell Malignancies
Chanan-Khan, A. A., & Cheson, B. D. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5367 · Cited by 178
Sauer, S., Erba, P. A., Petrini, M., Menrad, A., Giovannoni, L., Grana, C., Hirsch, B., Zardi, L., Paganelli, G., Mariani, G., et al. (2009) · Blood · doi:10.1182/blood-2008-06-160416 · Cited by 173
Circulating clonotypic B cells in classic Hodgkin lymphoma
Jones, R. J., Gocke, C. D., Kasamon, Y. L., Miller, C. B., Perkins, B. N., Barber, J. P., Vala, M. S., Gerber, J. M., Gellert, L. L., Siedner, M. J., et al. (2009) · Blood · doi:10.1182/blood-2008-11-189688 · Cited by 171
A pilot study of rituximab in patients with recurrent, classic Hodgkin disease
Younes, A., Romaguera, J. E., Hagemeister, F. B., McLaughlin, P. J., Rodriguez, M. A., Fiumara, P. F., Goy, A. H., Jeha, S., Manning, J. T., Jones, D. M., et al. (2003) · Cancer · doi:10.1002/cncr.11511 · Cited by 168
Gandhi, M. K., Moll, G., Smith, C., Dua, U., Lambley, E., Ramuz, O., Gill, D. S., Marlton, P. V., Seymour, J. F., & Khanna, R. (2007) · Blood · doi:10.1182/blood-2007-01-066100 · Cited by 164
Buglio, D., Georgakis, G. V., Hanabuchi, S., Arima, K., Khaskhely, N. M., Liu, Y.-J., & Younes, A. (2008) · Blood · doi:10.1182/blood-2008-01-133769 · Cited by 161
Muenst, S. E., Hoeller, S., Dirnhofer, S., & Tzankov, A. (2009) · Human Pathology · doi:10.1016/j.humpath.2009.03.025 · Cited by 161
Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues
Maggio, E. M., van den Berg, A., Diepstra, A., Kluiver, J. L., Visser, L., & Poppema, S. (2002) · Annals of Oncology · doi:10.1093/annonc/13.s1.52 · Cited by 157
Jundt, F., Anagnostopoulos, I., Bommert, K., Emmerich, F., Müller, G., Foss, H., Royer, H., Stein, H., & Dörken, B. (1999) · Blood · doi:10.1182/blood.v94.6.2065 · Cited by 153
Aldinucci, D., Lorenzon, D., Cattaruzza, L., Pinto, A., Gloghini, A., Carbone, A., & Colombatti, A. (2007) · International Journal of Cancer · doi:10.1002/ijc.23119 · Cited by 152
Self-citationCarbone, A., Gloghini, A., Gruss, H. J., & Pinto, A. (1995) · Europe PMC (PubMed Central) · Cited by 150
Self-citationFischer, M., Juremalm, M., Olsson, N., Backlin, C., Sundström, C., Nilsson, K., Enblad, G., & Nilsson, G. P. (2003) · International Journal of Cancer · doi:10.1002/ijc.11370 · Cited by 135
Functional expression of receptor activator of nuclear factor κB in Hodgkin disease cell lines
Fiumara, P. F., Snell, V., Li, Y., Mukhopadhyay, A., Younes, M., Gillenwater, A. M., Cabanillas, F., Aggarwal, B. B., & Younes, A. (2001) · Blood · doi:10.1182/blood.v98.9.2784 · Cited by 130
Pinto, A., Aldinucci, D., Gloghini, A., Zagonel, V., Degan, M., Improta, S., Juzbasic, S., Todesco, M., Perin, V., Gattei, V., et al. (1996) · Blood · doi:10.1182/blood.v88.9.3299.bloodjournal8893299 · Cited by 129
Self-citationSerum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22
Niens, M., Visser, L., Nolte, I. M., van der Steege, G., Diepstra, A., Cordano, P., Jarrett, R. F., Meerman, G. J. T., Poppema, S., & van den Berg, A. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06964.x · Cited by 129
Ma, Y., Visser, L., Roelofsen, H., de Vries, M., Diepstra, A., Imhoff, G. W. V., van der Wal, T., Luinge, M. A., Álvarez‐Llamas, G., Vos, H. J., et al. (2007) · Blood · doi:10.1182/blood-2007-09-112128 · Cited by 127
Matsui, T., Nakata, N., Nagai, S., Nakatani, A., Takahashi, M., Momose, T., Ohtomo, K., & Koyasu, S. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.060103 · Cited by 122
Treatment of Hodgkin lymphoma: the past, present, and future
Evens, A. M., Hutchings, M., & Diehl, V. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1186 · Cited by 120
Höpken, U. E., Foss, H., Meyer, D., Hinz, M., Leder, K., Stein, H., & Lipp, M. (2002) · Blood · doi:10.1182/blood.v99.4.1109 · Cited by 120
Casasnovas, O., Mounier, N., Brice, P., Diviné, M., Morschhauser, F., Gabarre, J., Blay, J., Voillat, L., Lederlin, P., Stamatoullas, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1331 · Cited by 118
Gattei, V., Degan, M., Gloghini, A., Iuliis, A. D., Improta, S., Rossi, F. M., Aldinucci, D., Perin, V., Serraino, D., Babare, R., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2048 · Cited by 117
Self-citationFrom Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential
Ré, D., Thomas, R. K., Behringer, K., & Diehl, V. (2005) · Blood · doi:10.1182/blood-2004-12-4750 · Cited by 116
Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin's disease
Carbone, A., Gloghini, A., Aldinucci, D., Gattei, V., Dalla‐Favera, R., & Gaïdano, G. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03456.x · Cited by 111
Self-citationLamprecht, B., Kreher, S., Anagnostopoulos, I., Jöhrens, K., Monteleone, G., Jundt, F., Stein, H., Janz, M., Dörken, B., & Mathas, S. (2008) · Blood · doi:10.1182/blood-2008-01-134783 · Cited by 110
Immune escape mechanisms in Hodgkin’s disease
Poppema, S., Potters, M., Visser, L., & van den Berg, A. (1998) · Annals of Oncology · doi:10.1093/annonc/9.suppl_5.s21 · Cited by 106
Cattaruzza, L., Gloghini, A., Olivo, K., Francia, R. D., Lorenzon, D., Filippi, R. D., Carbone, A., Colombatti, A., Pinto, A., & Aldinucci, D. (2009) · International Journal of Cancer · doi:10.1002/ijc.24389 · Cited by 104
Self-citationChemnitz, J. M., Driesen, J., Claßen, S., Riley, J. L., Debey, S., Beyer, M., Popov, A., Zander, T., & Schultze, J. L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3252 · Cited by 104
Immunobiology and Pathophysiology of Hodgkin Lymphomas
Poppema, S. (2005) · Hematology · doi:10.1182/asheducation-2005.1.231 · Cited by 102
Lymphocyte-rich classical Hodgkin's lymphoma: distinctive tumor and microenvironment markers
Nam‐Cha, S. H., Montes‐Moreno, S., Salcedo, M. T., Sanjuan, J., García, J. F., & Piris, M. A. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.54 · Cited by 100
Gruss, H., Hirschstein, D., Wright, B., Ulrich, D., Caligiuri, M. A., Barcos, M. P., Strockbine, L. D., Armitage, R. J., & Dower, S. (1994) · Blood · doi:10.1182/blood.v84.7.2305.2305 · Cited by 97
Khan, G. (2006) · Experimental Hematology · doi:10.1016/j.exphem.2005.11.008 · Cited by 94
Chemotherapeutic drugs and human tumor cells cytokine network
Levina, V. V., Su, Y., Nolen, B. M., Liu, X., Gordin, Y., Lee, M., Lokshin, A. E., & Gorelik, E. (2008) · International Journal of Cancer · doi:10.1002/ijc.23732 · Cited by 92
Hanamoto, H., Nakayama, T., Miyazato, H., Takegawa, S., Hieshima, K., Tatsumi, Y., Kanamaru, A., & Yoshie, O. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63187-2 · Cited by 92
The Role of Interleukin 13 in Classical Hodgkin Lymphoma
Skinnider, B., Kapp, U., & Mak, T. W. (2002) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190290026259 · Cited by 88
Schliemann, C., Wiedmer, A., Pedretti, M., Szczepanowski, M., Klapper, W., & Neri, D. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.06.025 · Cited by 88
Correale, P., Tagliaferri, P., Fioravanti, A., Vecchio, M. T. D., Remondo, C., Montagnani, F., Rotundo, M. S., Ginanneschi, C., Martellucci, I., Francini, E., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5278 · Cited by 81
Chemnitz, J. M., Eggle, D., Driesen, J., Claßen, S., Riley, J. L., Debey‐Pascher, S., Beyer, M., Popov, A., Zander, T., & Schultze, J. L. (2007) · Blood · doi:10.1182/blood-2006-12-064360 · Cited by 80
CCL5 promotes proliferation of MCF-7 cells through mTOR-dependent mRNA translation
Murooka, T. T., Rahbar, R., & Fish, E. N. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.07.035 · Cited by 78
HLA‐G protein expression as a potential immune escape mechanism in classical Hodgkin’s lymphoma
Diepstra, A., Poppema, S., Boot, M., Visser, L., Nolte, I. M., Niens, M., Meerman, G. J. T., & van den Berg, A. (2008) · Tissue Antigens · doi:10.1111/j.1399-0039.2008.01005.x · Cited by 77
CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues.
Gruss, H. J., Pinto, A., Gloghini, A., Wehnes, E., Wright, B., Boiani, N., Aldinucci, D., Gattei, V., Zagonel, V., Smith, C. A., et al. (1996) · Europe PMC (PubMed Central) · Cited by 74
Self-citationAlemtuzumab Therapy for Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia
Verstovšek, S., Tefferi, A., Kantarjian, H. M., Manshouri, T., Luthra, R., Pardanani, A. D., Quintás‐Cardama, A., Ravandi, F., Ault, P., Bueso-Ramos, C., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1302 · Cited by 71
Ma, Y., Visser, L., Blokzijl, T., Harms, G., Atayar, Ç., Poppema, S., & van den Berg, A. (2008) · Laboratory Investigation · doi:10.1038/labinvest.2008.24 · Cited by 70
Bone Marrow Microenvironment and Tumor Progression
Chantrain, C. F., Féron, O., Marbaix, É., & DeClerck, Y. A. (2008) · Cancer Microenvironment · doi:10.1007/s12307-008-0010-7 · Cited by 68
Serum YKL-40 and IL-6 Levels in Hodgkin Lymphoma
Biggar, R. J., Johansen, J. S., Smedby, K. E. E., Rostgaard, K., Chang, E. T., Adami, H., Glimelius, B. L. G., Molin, D. L., Hamilton-Dutoit, S. J., Melbye, M., et al. (2008) · PubMed Central · doi:10.1158/1078-0432.ccr-08-1026 · Cited by 67
A20 Protects From CD40-CD40 Ligand-Mediated Endothelial Cell Activation and Apoptosis
Longo, C. R., Arvelo, M. B., Patel, V. I., Daniel, S., Mahiou, J., Grey, S. T., & Ferran, C. J. (2003) · Circulation · doi:10.1161/01.cir.0000083718.76889.d0 · Cited by 66
The role of eosinophils in the pathobiology of Hodgkin's disease
Pinto, A., Aldinucci, D., Gloghini, A., Zagonel, V., Degan, M., Perin, V., Todesco, M., Iuliis, A. D., Improta, S., Sacco, C. S. P., et al. (1997) · Annals of Oncology · doi:10.1093/annonc/8.suppl_2.s89 · Cited by 62
Self-citationNovel treatment strategies for patients with relapsed classical Hodgkin lymphoma
Younes, A. (2009) · Hematology · doi:10.1182/asheducation-2009.1.507 · Cited by 61
Bräuninger, A., Wacker, H., Rajewsky, K., Küppers, R., & Hansmann, M. (2003) · PubMed · Cited by 61
Guo, F., Sun, A., Wang, W., He, J., Hou, J., Zhou, P., & Chen, Z. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.05.178 · Cited by 56
Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab
Ambrose, L. R., Morel, A., & Warrens, A. Ν. (2009) · Blood · doi:10.1182/blood-2009-02-203075 · Cited by 55
Interactions Between Tissue Fibroblasts in Lymph Nodes and Hodgkin/Reed-Sternberg Cells
Aldinucci, D., Lorenzon, D., Olivo, K., Rapanà, B., & Gattei, V. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190410001683633 · Cited by 55
Self-citationMarshall, N. A., Culligan, D. J., Tighe, J. E., Johnston, P. W., Barker, R. N., & Vickers, M. A. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.01.030 · Cited by 48
Rizzieri, D. A., Akabani, G., Zalutsky, M. R., Coleman, R. E., Metzler, S. D., Bowsher, J. E., Toaso, B., Anderson, E. L., Lagoo, A. S., Clayton, S., et al. (2004) · Blood · doi:10.1182/blood-2003-12-4264 · Cited by 47
Santos, D., Hatjiharissi, E., Tournilhac, O., Chemaly, M. A. Z., Leleu, X. P., Xu, L., Patterson, C. J., Branagan, A. R., Manning, R. J., Ho, A. W., et al. (2006) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2006.n.029 · Cited by 46
Khandani, A. H., Dunphy, C. H., Meteesatien, P., Dufault, D. L., Ivanović, M., & Shea, T. C. (2009) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e32832cc295 · Cited by 37
The role of interleukin-3 in classical Hodgkin's disease
Aldinucci, D., Olivo, K., Lorenzon, D., Poletto, D., Gloghini, A., Carbone, A., & Pinto, A. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190400013712 · Cited by 37
Self-citationInflammatory cells and immune microenvironment in malignant lymphoma
de Jong, D., & Enblad, G. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.02032.x · Cited by 37
Sánchez‐Espiridión, B., Sánchez‐Aguilera, A., Montalbán, C., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1119 · Cited by 37
The Potential Role of Innate Immunity in the Pathogenesis of Hodgkin's Lymphoma
Enblad, G., Molin, D. L., Glimelius, I. C., Fischer, M., & Nilsson, G. P. (2007) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2007.07.007 · Cited by 30
CD30 Is Involved in Inhibition of T-Cell Proliferation by Hodgkin’s Reed-Sternberg Cells
Su, C.-C., Chiu, H.-H., Chang, C., Chen, J.-C., & Hsu, S.-M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1337 · Cited by 30
Majka, M., Rozmysłowicz, T., Honczarenko, M., Ratajczak, J., Wasik, M. A., Gaulton, G. N., & Ratajczak, M. Z. (2000) · Leukemia · doi:10.1038/sj.leu.2401891 · Cited by 28
Regulatory T cells as therapeutic target in Hodgkin's lymphoma
Koenecke, C., Ukena, S. N., Ganser, A., & Franzke, A. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.6.769 · Cited by 19
Drug development for recurrent and refractory classical Hodgkin lymphoma
Wildes, T. M., & Bartlett, N. L. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190902756586 · Cited by 11
Cited by
The Warburg effect: 80 years on
Potter, M., Newport, E., & Morten, K. J. (2016) · Biochemical Society Transactions · doi:10.1042/bst20160094 · Cited by 499
The Inflammatory Chemokine CCL5 and Cancer Progression
Aldinucci, D., & Colombatti, A. (2014) · Mediators of Inflammation · doi:10.1155/2014/292376 · Cited by 438
Self-citationNitric oxide-mediated tumoricidal activity of murine microglial cells
Brantley, E. C., Guo, L., Zhang, C., Lin, Q., Yokoi, K., Langley, R. R., Kruzel, E., Maya, M., Kim, S. W., Kim, S.-J., et al. (2010) · Translational Oncology · doi:10.1593/tlo.10208 · Cited by 71
“Data suggest that these behavioral changes are largely dependent on the context of the specific tumor type and its microenvironment [19–22].”
BackgroundHude, I., Sasse, S., Bröckelmann, P. J., von Tresckow, B., Momotow, J., Engert, A., & Borchmann, S. (2018) · British Journal of Haematology · doi:10.1111/bjh.14705 · Cited by 27
Metadata
- Authors
- Aldinucci, D., Gloghini, A., Pinto, A., De Filippi, R., & Carbone, A.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2010-04-19
- Volume
- 221
- Issue
- 3
- Pages
- 248-263
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W1968101362
- Cited by
- 275
- References
- 91
- FWCI
- 15.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.